JCR Pharmaceuticals Co., Ltd.
Prices may be delayed up to 20 min. Not investment advice. News volume: articles in the 4Search index each day.
Key statistics
Against its peers
Compare in full ›| 4552.T | CUP.F | D4S.F | REC.VI | ON4.F | 4547.T | |
|---|---|---|---|---|---|---|
| Market cap | 64.55B | 65.86B | 31.06B | 11.03B | 6.28B | 161.53B |
| P/E (TTM) | — | 24.0 | 20.3 | 22.3 | 15.4 | 14.4 |
| Forward P/E | 14.4 | 0.3 | 46.1 | — | — | 17.6 |
| Price/book | 1.6 | 5.6 | 3.1 | 5.1 | 1.3 | 0.7 |
| Dividend yield | 3.97% | 1.93% | 3.57% | 2.67% | 3.63% | 3.46% |
| 1-year change | −17.24% | −1.62% | −17.43% | +4.74% | +18.01% | −6.36% |
| Today | +4.96% | +4.33% | +5.64% | −0.28% | +4.90% | +3.06% |
The closest companies by business and industry (Drug Manufacturers - General). Prices may be delayed up to 20 min.
Latest news
All 4552.T news ›Acumen Pharmaceuticals and JCR Pharmaceuticals Enter Strategic Collaboration, Option and License Agreement to Develop Enhanced Brain Delivery™ Therapy for Alzheimer’s Disease
Acumen and JCR aim to develop a product leveraging Acumen’s amyloid beta oligomer-selective antibody expertise and JCR’s transferrin-receptor-targeting blood-brain barrier-penetrating technology Preclinical candidate data expected in early…
JCR Pharmaceuticals Receives Marketing Authorization in Kuwait for IZCARGO™, a Blood-Brain Barrier-Penetrating Enzyme Replacement Therapy for Hunter Syndrome
- This approval follows the recent marketing authorization for IZCARGO™ in the United Arab Emirates - Kuwait is the second market outside Japan where IZCARGO™ has received approval, following the United Arab Emirates in July 2026. IZCARGO™…
From the 4Search news index, newest first.
In the news
Mentioned with
People in the coverage
Most coverage from
- biospace.com2
- en.ilsole24ore.com1
Finance and business coverage in the 4SEARCH.business news index: articles that name it in the headline, or in the text beside its ticker. Sentiment is the index's own reading of the latest 3 articles, not a forecast.